Max Schlueter

439 total citations
16 papers, 196 citations indexed

About

Max Schlueter is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Max Schlueter has authored 16 papers receiving a total of 196 indexed citations (citations by other indexed papers that have themselves been cited), including 3 papers in Pulmonary and Respiratory Medicine, 3 papers in Oncology and 3 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Max Schlueter's work include Diabetes Treatment and Management (3 papers), Biosimilars and Bioanalytical Methods (2 papers) and Rheumatoid Arthritis Research and Therapies (2 papers). Max Schlueter is often cited by papers focused on Diabetes Treatment and Management (3 papers), Biosimilars and Bioanalytical Methods (2 papers) and Rheumatoid Arthritis Research and Therapies (2 papers). Max Schlueter collaborates with scholars based in United Kingdom, Germany and Spain. Max Schlueter's co-authors include Nathaniel Henry, Núria González-Rojas, Michael Baldwin, Florian Voß, Michael J. Ostacher, Daisy Ng‐Mak, Pankaj Patel, Antony Loebel, Jelena Jovanović and Koo Wilson and has published in prestigious journals such as PLoS ONE, JAMA Network Open and Critical Reviews in Oncology/Hematology.

In The Last Decade

Max Schlueter

15 papers receiving 188 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Max Schlueter United Kingdom 8 56 40 32 30 29 16 196
Grace Kanzawa-Lee United States 13 46 0.8× 57 1.4× 8 0.3× 74 2.5× 35 1.2× 22 363
Lauren Piulson United States 10 42 0.8× 77 1.9× 10 0.3× 29 1.0× 18 0.6× 16 340
Kelliann C. Fee-Schroeder United States 7 46 0.8× 49 1.2× 8 0.3× 11 0.4× 65 2.2× 13 258
Jim Bonham United Kingdom 6 15 0.3× 39 1.0× 17 0.5× 5 0.2× 40 1.4× 7 168
Scott Capozza United States 6 78 1.4× 78 1.9× 10 0.3× 3 0.1× 88 3.0× 12 399
Susana Clemente Spain 8 51 0.9× 26 0.7× 21 0.7× 3 0.1× 49 1.7× 41 181
Laurence Girard France 7 21 0.4× 47 1.2× 7 0.2× 5 0.2× 14 0.5× 12 196
Chenghao Chu United States 9 133 2.4× 16 0.4× 20 0.6× 2 0.1× 25 0.9× 18 269
Yen-Yin Chou Taiwan 11 15 0.3× 87 2.2× 17 0.5× 5 0.2× 60 2.1× 21 283
Ana Joaquim Portugal 9 56 1.0× 26 0.7× 9 0.3× 6 0.2× 27 0.9× 37 239

Countries citing papers authored by Max Schlueter

Since Specialization
Citations

This map shows the geographic impact of Max Schlueter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Schlueter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Schlueter more than expected).

Fields of papers citing papers by Max Schlueter

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Max Schlueter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Schlueter. The network helps show where Max Schlueter may publish in the future.

Co-authorship network of co-authors of Max Schlueter

This figure shows the co-authorship network connecting the top 25 collaborators of Max Schlueter. A scholar is included among the top collaborators of Max Schlueter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Max Schlueter. Max Schlueter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Huygen, Frank J. P. M., et al.. (2024). Spinal Cord Stimulation vs Medical Management for Chronic Back and Leg Pain. JAMA Network Open. 7(11). e2444608–e2444608. 7 indexed citations
2.
3.
Nikolaidis, Georgios F., et al.. (2023). Cost-effectiveness of encorafenib with binimetinib in unresectable or metastatic BRAF-mutant melanoma. The European Journal of Health Economics. 25(4). 641–653. 4 indexed citations
4.
Assouline, Sarit, et al.. (2022). Validity of event-free survival as a surrogate endpoint in haematological malignancy: Review of the literature and health technology assessments. Critical Reviews in Oncology/Hematology. 175. 103711–103711. 4 indexed citations
5.
Schlueter, Max, et al.. (2020). The cost of cancer – A comparative analysis of the direct medical costs of cancer and other major chronic diseases in Europe. PLoS ONE. 15(11). e0241354–e0241354. 15 indexed citations
6.
Schlueter, Max, et al.. (2020). A modeling framework for the economic evaluation of baricitinib in moderate-to-severe rheumatoid arthritis. Expert Review of Pharmacoeconomics & Outcomes Research. 20(2). 221–228. 1 indexed citations
7.
Schlueter, Max, Amélie Beaudet, Evan Davies, Binu Gurung, & Andreas Karabis. (2020). Evidence synthesis in pulmonary arterial hypertension: a systematic review and critical appraisal. BMC Pulmonary Medicine. 20(1). 202–202. 5 indexed citations
8.
Schlueter, Max, et al.. (2019). <p>Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain</p>. ClinicoEconomics and Outcomes Research. Volume 11. 395–403. 7 indexed citations
9.
Schlueter, Max, et al.. (2019). Static security evaluation of an industrial web application. publish.UP (University of Potsdam). 1952–1961. 1 indexed citations
10.
Schlueter, Max, et al.. (2017). Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK. Diabetes Therapy. 8(3). 513–530. 18 indexed citations
11.
Ostacher, Michael J., et al.. (2017). Lurasidone compared to other atypical antipsychotic monotherapies for bipolar depression: A systematic review and network meta-analysis. The World Journal of Biological Psychiatry. 19(8). 586–601. 32 indexed citations
12.
Henry, Nathaniel, et al.. (2017). Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden. Journal of Medical Economics. 21(4). 318–325. 27 indexed citations
13.
14.
Mezquita‐Raya, Pedro, et al.. (2016). Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type-2 Diabetes Mellitus in Spain: A Cost-Effectiveness Analysis. Value in Health. 19(7). A674–A674. 1 indexed citations
15.
Schlueter, Max, et al.. (2016). Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: a systematic review and network meta-analysis. Therapeutic Advances in Respiratory Disease. 10(2). 89–104. 44 indexed citations
16.
Henry, Nathaniel, Max Schlueter, Julia Lowin, et al.. (2014). Cost of unintended pregnancy in Norway: a role for long-acting reversible contraception. Journal of Family Planning and Reproductive Health Care. 41(2). 109–115. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Grace Kanzawa-Lee Breakdown of academic impact, for papers by Lauren Piulson Breakdown of academic impact, for papers by Kelliann C. Fee-Schroeder Breakdown of academic impact, for papers by Jim Bonham Breakdown of academic impact, for papers by Scott Capozza Breakdown of academic impact, for papers by Susana Clemente Breakdown of academic impact, for papers by Laurence Girard Breakdown of academic impact, for papers by Chenghao Chu Breakdown of academic impact, for papers by Yen-Yin Chou Breakdown of academic impact, for papers by Ana Joaquim
Rankless by CCL
2026